Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease

H. Lee, Y. M. Sohn, J. Y. Ko, S. Y. Lee, B. W. Jhun, H. Y. Park, K. Jeon, D. H. Kim, S. Y. Kim, J. E. Choi, I. J. Moon, SungJae Shin, H. J. Park, W. J. Koh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE : To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS : With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax, target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONC LUS ION: Our results suggest that once-daily AMK for 4 weeks with a target max of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.

Original languageEnglish
Pages (from-to)818-824
Number of pages7
JournalInternational Journal of Tuberculosis and Lung Disease
Volume21
Issue number7
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Amikacin
Mycobacterium
Lung Diseases
Therapeutics
Republic of Korea
Tinnitus
Hearing Loss
Tertiary Care Centers
Multivariate Analysis
Pharmacokinetics
Odds Ratio
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Lee, H. ; Sohn, Y. M. ; Ko, J. Y. ; Lee, S. Y. ; Jhun, B. W. ; Park, H. Y. ; Jeon, K. ; Kim, D. H. ; Kim, S. Y. ; Choi, J. E. ; Moon, I. J. ; Shin, SungJae ; Park, H. J. ; Koh, W. J. / Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. In: International Journal of Tuberculosis and Lung Disease. 2017 ; Vol. 21, No. 7. pp. 818-824.
@article{b03f1760ff544029a96eb779137ac405,
title = "Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease",
abstract = "SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE : To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS : With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax, target of 55-65 μg/ml was achieved in 31.3{\%} (15/48) of patients in the first week, 68.8{\%} (33/48) in week 2, 91.7{\%} (44/48) in week 3 and 95.8{\%} (46/48) in week 4. Transient nephrotoxicity developed in 6.3{\%} (3/48) of patients and ototoxicity in 25.0{\%} (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONC LUS ION: Our results suggest that once-daily AMK for 4 weeks with a target max of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.",
author = "H. Lee and Sohn, {Y. M.} and Ko, {J. Y.} and Lee, {S. Y.} and Jhun, {B. W.} and Park, {H. Y.} and K. Jeon and Kim, {D. H.} and Kim, {S. Y.} and Choi, {J. E.} and Moon, {I. J.} and SungJae Shin and Park, {H. J.} and Koh, {W. J.}",
year = "2017",
month = "7",
day = "1",
doi = "10.5588/ijtld.16.0791",
language = "English",
volume = "21",
pages = "818--824",
journal = "International Journal of Tuberculosis and Lung Disease",
issn = "1027-3719",
publisher = "International Union against Tubercul. and Lung Dis.",
number = "7",

}

Lee, H, Sohn, YM, Ko, JY, Lee, SY, Jhun, BW, Park, HY, Jeon, K, Kim, DH, Kim, SY, Choi, JE, Moon, IJ, Shin, S, Park, HJ & Koh, WJ 2017, 'Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease', International Journal of Tuberculosis and Lung Disease, vol. 21, no. 7, pp. 818-824. https://doi.org/10.5588/ijtld.16.0791

Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. / Lee, H.; Sohn, Y. M.; Ko, J. Y.; Lee, S. Y.; Jhun, B. W.; Park, H. Y.; Jeon, K.; Kim, D. H.; Kim, S. Y.; Choi, J. E.; Moon, I. J.; Shin, SungJae; Park, H. J.; Koh, W. J.

In: International Journal of Tuberculosis and Lung Disease, Vol. 21, No. 7, 01.07.2017, p. 818-824.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease

AU - Lee, H.

AU - Sohn, Y. M.

AU - Ko, J. Y.

AU - Lee, S. Y.

AU - Jhun, B. W.

AU - Park, H. Y.

AU - Jeon, K.

AU - Kim, D. H.

AU - Kim, S. Y.

AU - Choi, J. E.

AU - Moon, I. J.

AU - Shin, SungJae

AU - Park, H. J.

AU - Koh, W. J.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE : To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS : With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax, target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONC LUS ION: Our results suggest that once-daily AMK for 4 weeks with a target max of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.

AB - SETTING: Tertiary referral centre, Samsung Medical Center, South Korea. OBJECTIVE : To evaluate the pharmacokinetic parameters and toxicities of once-daily amikacin (AMK) dosing for lung disease due to Mycobacterium abscessus. DESIGN: A retrospective review of 48 patients with M. abscessus lung disease who received once-daily AMK for 4 weeks between January 2012 and June 2015. RESULTS : With a starting dose of 15 mg/kg/day and adjustment of AMK dose according to the peak serum level (Cmax), the Cmax, target of 55-65 μg/ml was achieved in 31.3% (15/48) of patients in the first week, 68.8% (33/48) in week 2, 91.7% (44/48) in week 3 and 95.8% (46/48) in week 4. Transient nephrotoxicity developed in 6.3% (3/48) of patients and ototoxicity in 25.0% (6/24), which was determined by audiogram as hearing loss, asymptomatic in five patients and tinnitus in one. Multivariate analysis revealed that the highest drug concentration 12 h after administration was significantly associated with the development of toxicities (adjusted odds ratio 1.862, P = 0.047). CONC LUS ION: Our results suggest that once-daily AMK for 4 weeks with a target max of 55-65 μg/ml can be used in patients with M. abscessus lung disease, with careful monitoring of toxicity.

UR - http://www.scopus.com/inward/record.url?scp=85021095721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021095721&partnerID=8YFLogxK

U2 - 10.5588/ijtld.16.0791

DO - 10.5588/ijtld.16.0791

M3 - Article

VL - 21

SP - 818

EP - 824

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

SN - 1027-3719

IS - 7

ER -